What drives the decision to optimise biological treatment in children and youngsters with juvenile idiopathic arthritis? A discrete-choice experiment

Horton, 2017, Attitudes and approaches for withdrawing drugs for children with clinically inactive nonsystemic JIA: a survey of the childhood arthritis and rheumatology research alliance, J Rheumatol, 44, 352, 10.3899/jrheum.161078 Cai, 2013, Clinical trial of etanercept tapering in juvenile idiopathic arthritis during remission, Rheumatol Int, 33, 2277, 10.1007/s00296-012-2642-7 Broughton, 2012, Defining juvenile idiopathic arthritis remission and optimum time for disease-modifying anti-rheumatic drug withdrawal: why we need a consensus, Paediatr Drugs, 14, 7, 10.2165/11595980-000000000-00000 Gonzalez-Alvaro, 2015, Spanish Rheumatology Society and Hospital Pharmacy Society Consensus on recommendations for biologics optimization in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis, Rheumatology (Oxford), 54, 1200, 10.1093/rheumatology/keu461 Halyabar, 2019, Treatment withdrawal following remission in juvenile idiopathic arthritis: a systematic review of the literature, Paediatr Drugs, 10.1007/s40272-019-00362-6 Baszis, 2011, Clinical outcomes after withdrawal of anti-tumor necrosis factor alpha therapy in patients with juvenile idiopathic arthritis: a twelve-year experience, Arthritis Rheum, 63, 3163, 10.1002/art.30502 Chang, 2015, Impact of medication withdrawal method on flare-free survival in patients with juvenile idiopathic arthritis on combination therapy, Arthritis Care Res (Hoboken), 67, 658, 10.1002/acr.22477 Simonini, 2017, Flares after withdrawal of biologic therapies in juvenile idiopathic arthritis: clinical and laboratory correlates of remission duration, Arthritis Care Res (Hoboken) Bridges, 2011, Conjoint analysis applications in health – a checklist: a report of the ISPOR Good Research Practices for Conjoint Analysis Task Force, Value Health, 14, 403, 10.1016/j.jval.2010.11.013 Louder, 2016, Patient preferences regarding rheumatoid arthritis therapies: a conjoint analysis, Am Health Drug Benefits, 9, 84 Kievit, 2010, Factors that influence rheumatologists’ decisions to escalate care in rheumatoid arthritis: results from a choice-based conjoint analysis, Arthritis Care Res (Hoboken), 62, 842, 10.1002/acr.20123 Fransen, 2016, What should be the cut point for classification criteria of studies in gout? A conjoint analysis, Arthritis Care Res (Hoboken), 68, 1731, 10.1002/acr.22875 Taylor, 2016, Pros and cons of conjoint analysis of discrete choice experiments to define classification and response criteria in rheumatology, Curr Opin Rheumatol, 28, 117, 10.1097/BOR.0000000000000259 Wallace, 2004, Preliminary criteria for clinical remission for select categories of juvenile idiopathic arthritis, J Rheumatol, 31, 2290 Ruperto, 2008, Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trial, Lancet, 372, 383, 10.1016/S0140-6736(08)60998-8 Yokota, 2008, Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial, Lancet, 371, 998, 10.1016/S0140-6736(08)60454-7 Foell, 2010, Methotrexate withdrawal at 6 vs 12 months in juvenile idiopathic arthritis in remission: a randomized clinical trial, JAMA, 303, 1266, 10.1001/jama.2010.375 Brunner, 2015, Efficacy and safety of tocilizumab in patients with polyarticular-course juvenile idiopathic arthritis: results from a phase 3, randomised, double-blind withdrawal trial, Ann Rheum Dis, 74, 1110, 10.1136/annrheumdis-2014-205351 Amarilyo, 2016, Biological agents in polyarticular juvenile idiopathic arthritis: a meta-analysis of randomized withdrawal trials, Semin Arthritis Rheum, 46, 312, 10.1016/j.semarthrit.2016.07.001 Brunner, 2018, Subcutaneous golimumab for children with active polyarticular-course juvenile idiopathic arthritis: results of a multicentre, double-blind, randomised-withdrawal trial, Ann Rheum Dis, 77, 21, 10.1136/annrheumdis-2016-210456 Prince, 2009, When and how to stop etanercept after successful treatment of patients with juvenile idiopathic arthritis, Ann Rheum Dis, 68, 1228, 10.1136/ard.2008.101030 Garcia-Vidal, 2019, Artificial intelligence to support clinical decision-making processes, EBioMedicine, 46, 27, 10.1016/j.ebiom.2019.07.019 Postepski, 2013, Clinical remission in juvenile idiopathic arthritis after termination of etanercept, Rheumatol Int, 33, 2657, 10.1007/s00296-012-2468-3